| Prevention and treatment of monkeypox JG Rizk, G Lippi, BM Henry, DN Forthal, Y Rizk Drugs 82 (9), 957-963, 2022 | 559 | 2022 |
| Pharmaco-immunomodulatory therapy in COVID-19 JG Rizk, K Kalantar-Zadeh, MR Mehra, CJ Lavie, Y Rizk, DN Forthal Drugs 80, 1267-1292, 2020 | 341 | 2020 |
| Clinical characteristics and pharmacological management of COVID-19 vaccine–induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review JG Rizk, A Gupta, P Sardar, BM Henry, JC Lewin, G Lippi, CJ Lavie JAMA cardiology 6 (12), 1451-1460, 2021 | 112 | 2021 |
| Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. JG Rizk, DN Forthal, K Kalantar-Zadeh, MR Mehra, CJ Lavie, Y Rizk, ... Drug discovery today 26 (2), 593-603, 2021 | 74 | 2021 |
| Cefiderocol: a siderophore cephalosporin RM El-Lababidi, JG Rizk Annals of Pharmacotherapy 54 (12), 1215-1231, 2020 | 72 | 2020 |
| Blood lactate concentration in COVID-19: a systematic literature review G Carpenè, D Onorato, R Nocini, G Fortunato, JG Rizk, BM Henry, G Lippi Clinical Chemistry and Laboratory Medicine (CCLM) 60 (3), 332-337, 2022 | 50 | 2022 |
| Novel approaches to management of hyperkalaemia in kidney transplantation J Rizk, D Quan, S Gabardi, Y Rizk, K Kalantar-Zadeh Current opinion in nephrology and hypertension 30 (1), 27-37, 2021 | 20 | 2021 |
| Low-dose aspirin for early COVID-19: does the early bird catch the worm? JG Rizk, CJ Lavie, A Gupta Expert Opinion on Investigational Drugs 30 (8), 785-788, 2021 | 17 | 2021 |
| Angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use associated with reduced mortality and other disease outcomes in US veterans with COVID-19 JG Rizk, C Wenziger, D Tran, L Hashemi, H Moradi, E Streja, A Ahluwalia Drugs, 1-12, 2022 | 16 | 2022 |
| Monkeypox transmission—what we know so far P Venkatesan The Lancet Respiratory Medicine 10 (11), e101, 2022 | 15 | 2022 |
| Anticoagulation management strategies in heart transplantation J Rizk, MR Mehra Progress in cardiovascular diseases 63 (3), 210-218, 2020 | 15 | 2020 |
| To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years JG Rizk, A Gupta, JG Lazo Jr, P Sardar, BM Henry, CJ Lavie, MB Effron Seminars in Thrombosis and Hemostasis 49 (01), 062-072, 2023 | 12 | 2023 |
| Serum creatinine-to-cystatin-C ratio as a potential muscle mass surrogate and racial differences in mortality JG Rizk, E Streja, C Wenziger, MG Shlipak, KC Norris, ST Crowley, ... Journal of Renal Nutrition 33 (1), 69-77, 2023 | 12 | 2023 |
| The next frontier in vaccine safety and VAERS: lessons from COVID-19 and ten recommendations for action JG Rizk, CE Barr, Y Rizk, JC Lewin Vaccine 39 (41), 6017, 2021 | 12 | 2021 |
| Correction to: prevention and treatment of Monkeypox JG Rizk, G Lippi, BM Henry, DN Forthal, Y Rizk Drugs 82 (12), 1343, 2022 | 10 | 2022 |
| Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients JG Rizk, JG Lazo, D Quan, S Gabardi, Y Rizk, E Streja, CP Kovesdy, ... Reviews in Endocrine and Metabolic Disorders, 1-14, 2021 | 9 | 2021 |
| Heart transplantation in the Middle East Gulf region F Bader, B Atallah, J Rizk, W AlHabeeb Transplantation 102 (7), 1023-1026, 2018 | 8 | 2018 |
| Authors’ Reply to Vrachatis et al.“Pharmaco-Immunomodulatory Therapy in COVID-19” JG Rizk, K Kalantar-Zadeh, MR Mehra, CJ Lavie, Y Rizk, DN Forthal Drugs 80, 1501-1503, 2020 | 7 | 2020 |
| Proposal for a Simple Algorithmic Approach to Manage Drug–Drug Interactions of Oral Anticoagulants with Nirmatrelvir/Ritonavir in COVID-19 Outpatients JG Rizk, JG Lazo Jr, A Gupta, CJ Lavie, MB Effron Seminars in Thrombosis and Hemostasis 49 (01), 085-088, 2023 | 5 | 2023 |
| Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath KC Chiang, JG Rizk, DJ Nelson, L Krishnamurti, S Subbian, JD Imig, ... Expert opinion on therapeutic targets 26 (1), 13-28, 2022 | 5 | 2022 |
Brandon Michael Henry, M.D.Cincinnati Children's Hospital Medical Center在 cchmc.org 的电子邮件经过验证
